Compare AbbVie Inc (ABBV) vs iShares MBS ETF (MBB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs iShares MBS ETF — how do they compare? AbbVie Inc trades at $253.76 (market cap $449.91B), while iShares MBS ETF trades at $93.64. The key difference: AbbVie Inc pays a 2.72% dividend while iShares MBS ETF pays none, and AbbVie Inc is trading nearer its 52-week high, iShares MBS ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | MBB | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | — |
52-Week High | $261.07 | $96.91 |
52-Week Low | $184.85 | $92.46 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
MBB (iShares MBS ETF) trades at $93.84, down 0.31% with a bearish technical outlook from moving averages. The ETF shows neutral oscillator signals with RSI at 46.40. Recent institutional activity includes mixed positioning changes, with Comerica Bank reducing its stake by 12.9% while Concurrent Investment Advisors increased its position by 75.4% in Q4 2026. The fund focuses on mortgage-backed securities and has maintained consistent dividend payments.
The outlook for MBB remains cautious due to bearish technical signals and mixed institutional sentiment. Investment opportunities include exposure to the real estate sector with a 4% monthly yield potential, though risks involve interest rate sensitivity and mortgage market volatility. The ETF's defensive characteristics may appeal to income-focused investors seeking diversification.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →
